Navigating Regulatory Complexities in Radiopharmaceutical Development
- Clarifying the unique regulatory requirements for radiopharmaceuticals versus conventional therapies like ADCs
- Aligning early-phase trial designs with risk-based, patient-centric approaches to accelerate first-in-human studies
- Facilitating global harmonization by comparing regulatory frameworks in the US, Europe, China, and Australia to reduce development delays